Ginkgo Bioworks posted Q2 2026 revenue of USD 20 million, down 48% on ongoing program rationalization tied to restructuring.
GAAP net loss from continuing operations widened to USD 57 million.
Adjusted EBITDA loss widened to USD 36 million.
Cash, cash equivalents and marketable securities totaled USD 302 million at June 30, 2026; full-year cash burn outlook reaffirmed at USD 150-125 million.
Business and contract updates
Won government-backed autonomous lab work at MIT, Caltech, Northwestern and the University of Maryland; began a USD 47 million build at PNNL’s EMSL.
DNA•
